Pacific Edge bladder test validation bodes well for US sales
Dunedin-based DNA diagnostic test business Pacific Edge has received independent clinical confirmation that its bladder cancer detection test is at least as effective as other methods.
The validation in the American Journal of Urology could be worth up to $100 million a year in five years' time for Pacific Edge's Cxbladder test, the company said.
Chief executive David Darling says the peer-reviewed validation that the company's urine-based test has the ability to detect nearly all tumours of concern to urologists is very important for Pacific Edge's US implementation strategy.
"The Journal of Urology is widely read by urologists, medical insurers and often those bladder cancer patients who are looking for an accurate, more convenient and less intrusive method of detecting bladder cancer," he said.
There are 17,000 urologists in America, compared to 300 in total across New Zealand and Australia, and Cxbladder will be formally launched when its purpose-built testing laboratory in Hershey, Pennsylvania, receives certification early next year.
Darling said this laboratory is very close to the Pennsylvania State University Hospital, one of four integrated cancer facilities in America.
Cxbladder's clinical validation is a major milestone Darling said, as "urologists love the technology as it is easy to use and very accurate," compared to alternatives.
Patients with bladder cancer or pre-cancer symptoms often need to have multiple visits to an urologist. However, a Cxbladder test can be achieved from a urine sample collected at a patient's home and the sample sent to Pacific Edge for analysis.
"This is a massive market, where there are many challenges to doing business," Darling said. "But the rewards are phenomenal and it is a great opportunity for our shareholders."
The shares rose 5.3 percent to 20 cents on the NZX, valuing the company at $54.9 million.
Comments from our readers
No comments yet
Add your comment:
Pacific Edge shares soar to new record on optimism about potential US growth
Pacific Edge at record-high after signing 2nd US health provider network
Masfen, long-term Pacific Edge backer, sells 10 mln shares near record high
Pacific Edge sees $100M revenue from US in five years
Pacific Edge US lab complete, seeks regulatory approval
Pacific Edge signs Auckland distribution agreement for bladder test
Pacific Edge 1H loss narrows as company eyes US market for bladder test
Pacific Edge has pipeline of new products to follow new cancer-test patents
Pacific Edge secures patent for colorectal cancer detection technology